Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
jueves, octubre 22
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Ligand Pharmaceuticals Inc
LGND
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$314.78
8.38
2.73%
Últ. Act.: Oct 21, 4:20 PM
$314.78
8.38
2.73%
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
Privacy Manager
Ganancias:
Beneficios de Q3 2026 dentro de 7 días de ahora en jue oct 29th, antes de la apertura del mercado
Conferencia telefónica:
Conferencia telefónica programada para dentro de 7 días a las 8:30 a. m.
Haz clic para ver el webcast
Ligand Pharmaceuticals Financials
Ligand Pharmaceuticals (LGND) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Ligand Pharmaceuticals Raises FY2026 Adj EPS Guidance from $8.50-$9.50 to $9.00-$9.50 vs $9.16 Est; Affirms FY2026 Sales Guidance of $270.000M-$310.000M vs $288.559M Est
Ligand Pharmaceuticals (NASDAQ:LGND) raises FY2026 Adj EPS guidance from $8.50-$9.50 to $9.00-$9.50 vs $9.16 analyst estimate. Affirms FY2026 sales outlook from $270.000 million-$310.000 million to $270.000
Benzinga Newsdesk
PRO
Ligand Pharmaceuticals Q2 Adj. EPS $2.37 Beats $1.84 Estimate, Sales $63.693M Beat $60.765M Estimate
Benzinga Newsdesk
PRO
Ligand Pharmaceuticals Affirms FY2026 Adj EPS Guidance of $8.50-$9.50 vs $9.13 Est; Affirms FY2026 Sales Guidance of $270.000M-$310.000M vs $281.535M Est
Ligand Pharmaceuticals (NASDAQ:LGND) affirms FY2026 Adj EPS guidance from $8.50-$9.50 to $8.50-$9.50 vs $9.13 analyst estimate. Affirms FY2026 sales outlook from $270.000 million-$310.000 million to $270.000
Benzinga Newsdesk
PRO
Ligand Pharmaceuticals Q1 Adj. EPS $1.63 Misses $1.82 Estimate, Sales $51.722M Miss $58.696M Estimate
Ligand Pharmaceuticals (NASDAQ:LGND) reported quarterly earnings of $1.63 per share which missed the analyst consensus estimate of $1.82 by 10.44 percent. This is a 22.56 percent increase over earnings of $1.33 per share
Benzinga Newsdesk
PRO
Earlier Monday, Ligand Pharmaceuticals Raises FY2026 Adj EPS Guidance from $8.00-$9.00 to $8.50-$9.50 vs $9.40 Est; Raises FY2026 Sales Guidance from $245M-$285M to $270M-$310M vs $266.714M Est
Benzinga Newsdesk
PRO
Ligand Pharmaceuticals Affirms FY2026 Adj EPS Guidance of $8.00-$9.00 vs $8.29 Est; Affirms FY2026 Sales Guidance of $245.000M-$285.000M vs $265.679M Est.
Ligand Pharmaceuticals (NASDAQ:LGND) affirms FY2026 Adj EPS guidance from $8.00-$9.00 to $8.00-$9.00 vs $8.29 analyst estimate. Affirms FY2026 sales outlook from $245.000 million-$285.000 million to $245.000
Benzinga Newsdesk
